IMVT•benzinga•
Immunovant Reported Topline Results From Its Phase 3 Study Of Batoclimab In Myasthenia Gravis And Initial Results From Period 1 Of Its Phase 2B Study In Chronic Inflammatory Demyelinating Polyneuropathy
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on March 19, 2025 by benzinga